0000950149-01-501420.txt : 20011009 0000950149-01-501420.hdr.sgml : 20011009 ACCESSION NUMBER: 0000950149-01-501420 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010913 ITEM INFORMATION: Other events FILED AS OF DATE: 20010921 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 1741625 BUSINESS ADDRESS: STREET 1: 901 MARINER'S ISLAND BLVD. STREET 2: SUITE 205 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 901 MARINER'S ISLAND BLVD. STREET 2: SUITE 205 CITY: SAN MATEO STATE: CA ZIP: 94404 8-K 1 f75905e8-k.htm 8-K e8-k
Table of Contents

SECURITIES AND EXCHANGE COMMISSION
 
Washington, DC 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of Earliest Event Reported): September 13, 2001
 

SCICLONE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

         
California
(State or other jurisdiction of
incorporation)		   0-19825
(Commission File No.) 		  94-3116852
(IRS Employer
Identification No.)

901 Mariner’s Island Boulevard, Suite 205
San Mateo, California 94404
(Address of principal executive offices) (Zip Code)
 
 
Registrant’s telephone number, including area code: (650) 358-3456

Item 5. Other Events.
SIGNATURES

Item 5. Other Events.

     SciClone Pharmaceuticals, Inc. (the “Company”) received a lump sum payment equal to $3,225,000 in full satisfaction of an outstanding promissory note (the “Note”)(the Note and Note holder were previously described in the Company’s Annual Report on Form 10-K for the year ended December 31, 1999), and all claims related to the Note were resolved in connection with such payment. Prior to this lump sum payment, the Company received $720,000 in principal and interest payments on the Note. The Note represented the balance of principal and interest on a loan to the Note holder that had been written off in a non-cash charge to earnings in the fourth quarter of 1998. The Company will recognize the amount of the Note payment as other non-operating income for the quarterly period ending September 30, 2001.

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
  SCICLONE PHARMACEUTICALS, INC.
 
 
Date: September 21, 2001 By:  /s/ Richard A. Waldron
 
  Richard A. Waldron
Chief Financial Officer and Secretary